Kokoreva L N, Zmyzgova A V, Shalygina N B, Maksimov S L
Zh Mikrobiol Epidemiol Immunobiol. 1994 Jan-Feb(1):55-9.
The results of the examination of 20 patients having chronic hepatitis delta (CHD) with the disease lasting 1-2 years (8 patients) and 3-6 years (12 patients) are presented. In most of the patients of both groups, irrespective of the duration of the disease, the development of severe hepatic lesions has been established. The morphological study has revealed in 45% of the examined patients the presence of chronic active hepatitis leading to the cirrhosis if the liver. A prolonged course of treatment (8-12 months) with reaferon (recombinant interferon alpha 2, obtained by gene engineering technique), injected intramuscularly in a dose of 1 x 10(6) I.U. once or twice a week, has proved to be effective in 47% of CHD patients aged 15-30 years with a weak expression of autoimmune process. It is recommended that interferon therapy in patients with CHD requires individual indications.
本文呈现了对20例慢性丁型肝炎（CHD）患者的检查结果，这些患者病程为1至2年（8例）和3至6年（12例）。在两组的大多数患者中，无论病程长短，均已确定有严重肝脏病变的发生。形态学研究显示，45%的受检患者存在慢性活动性肝炎，若病情持续发展可导致肝硬化。对于15至30岁、自身免疫过程表达较弱的CHD患者，采用重组干扰素α2（通过基因工程技术获得）进行为期8至12个月的长期治疗（每周肌肉注射1×10⁶国际单位，一次或两次），结果证明47%的患者有效。建议CHD患者的干扰素治疗需依据个体指征进行。
